Chargement en cours...
Cytokine Release Syndrome: Current Perspectives
Chimeric antigen receptor T cell (CART) therapy represents a novel and a paradigm-shifting approach to treating cancer. Recent clinical successes have widened the applicability of CD19 CART cells for the treatment of relapsed/refractory B-cell NHL, namely tisagenleclucel and axicabtagene ciloleucel....
Enregistré dans:
| Publié dans: | Immunotargets Ther |
|---|---|
| Auteurs principaux: | , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Dove
2019
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6825470/ https://ncbi.nlm.nih.gov/pubmed/31754614 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/ITT.S202015 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|